Comments
Caplin Point Laboratories has received the Establishment Inspection Report from the US health regulator for its Gummidopoondi facility in Chennai.
“Caplin Point has received the Establishment Inspection Report (EIR) from USFDA (United States Food and Drug Administration) for inspection carried out during October 21-27, 2016, at its sterile injectable plant at Gummidopoondi in Tamil Nadu,” Caplin Point Laboratories said in a filing to the BSE today.
“This will pave the way for our entry into the largest pharma market in the world,” Caplin Point Laboratories Chairman C C Paarthipan said.
USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed.
Shares of Caplin Point Laboratories were trading at Rs 397.30 on BSE, up 2.60 per cent from their previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.